Hoth Therapeutics (NASDAQ: HOTH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.110 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Hoth Therapeutics (NASDAQ: HOTH) through any online brokerage.
Other companies in Hoth Therapeutics’s space includes: Cingulate (NASDAQ:CING), Graybug Vision (NASDAQ:GRAY), Dermata Therapeutics (NASDAQ:DRMA), Baudax Bio (NASDAQ:BXRX) and Kiora Pharmaceuticals (NASDAQ:KPRX).
The latest price target for Hoth Therapeutics (NASDAQ: HOTH) was reported by EF Hutton on Thursday, March 31, 2022. The analyst firm set a price target for 2.50 expecting HOTH to rise to within 12 months (a possible 502.41% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Hoth Therapeutics (NASDAQ: HOTH) is $0.415 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Hoth Therapeutics.
Hoth Therapeutics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Hoth Therapeutics.
Hoth Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.